Mohammed A Hussein¹*, Nada M El-Laban¹, Lamiaa H Elabody¹, Amany M Ghazal¹, Basant S Mohamed¹, Azhar A Mohamed¹, Lamiaa Y Elhalafwy¹, Sanaa M Elsayad¹, Amal S Othman² and Ali A Ali³

¹1Department of Biochemistry, Faculty of Applied Medical Science, October 6^th University, Egypt
²2Department of Med Labs, Faculty of Applied Medical Science, October 6^th University, Egypt
³3Vice President of Post Graduate Studies, October 6 University, Egypt

*Corresponding Author: Mohammed A Hussein, Professor of Biochemistry and Vice Dean for Post-graduate Studies and Scientific Research, Faculty of Applied Medical Sciences, October 6 University, Egypt.

Received: April 22, 2021; Published: June 11, 2021

Abstract

Neurodegenerative disorder clinically characterized by progressive cognitive and memory dysfunction. This study investigated the effect of Jasonia montana ethanolic extract (JMEE) on Ca‑, Mg⁺² and Na⁺, K⁺-ATPase and acetylcholinesterase (AChE) activities as well as β amyloid1-42 level in brain hippocampus of adult rats exposed to SCO. Rats were exposed to SCO (3.0 mg/Kg) and JMEE (150 mg/Kg) by gavage for 14 days. Rats were randomly divided into six groups with 6 rats in each: [Saline], [saline/SCO (3.0 mg/kg)], [saline/SCO (3.0 mg/kg)/JMEE (150 mg/kg,)], [saline/SCO (3.0 mg/kg)/ DHC (3 mg/kg)] and [saline/SCO (3.0 mg/kg)/JMEE (150 mg/kg,)/ DHC (3 mg/kg)]. Results demonstrated that plasma TC, TG as well as brain hippocampus levels of AChE, MAO, βA1-42, TBARS. Also, the results showed that a significant depletion of plasma HDL-C as well as brain hippocampus levels of phospholipids, GSH, ACh, Ca⁺², Mg⁺² and Na⁺, K⁺-ATPase. Treatment with JMEE (150 mg/Kg) prevented the increase in TC, TG, AChE, MAO, β amyloid1-42, TBARS activity when compared to SCO-treated group. JMEE treatment prevented the SCO-induced decrease in Ca⁺², Mg⁺² and Na⁺, K⁺-ATPase activities as well as GSH, HDL-C, ACh and phospholipids in SCO-treated group when compared to normal group. Our data showed that JMEE have a protector effect against SCO induced neurodegenerative. Also, Jasonia Montana is a promising therapeutic agent to attenuate neurological disorders associated with SCO induced dementia.

Keywords:Jasonia Montana; Antioxidant; Scopolamine; Acetylcholine Esterase; Monoamine Oxidase and Dementia

References

1. Francis C., et al. “Beneficial effects of berry fruit polyphenols on neuronal and behavioral aging”. Journal of Agricultural and Food Chemistry 14 (2006): 2251-2255.
2. Serrano-Pozo A., et al. “Neuropathological alterations in Alzheimer disease”. Cold Spring Harbor Perspectives in Medicine 1 (2011): a006189.
3. Suh YH and Checler F. “Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease”. Pharmacology Review 54 (2002): 469-525.
4. Birringer M. “Hormetics: dietary triggers of an adaptive stress response”. Pharmaceutical Research 11 (2011): 2680-2694.
5. Koehn FE. “High impact technologies for natural products screening”. Progress in Drug Research 175 (2011): 177-210.
6. Bantscheff M., et al. “Quantitative mass spectrometry in proteomics: a critical review”. Analytical and Bioanalytical Chemistry 389 (2007): 1017-1031.
7. Choi YS., et al. “Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer’s disease biomarker candidates”. Journal of Chromatography A 930 (2013): 129-135.
8. Chiasserini D., et al. “CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer’s disease”. Journal of Alzheimer's Disease 22 (2010): 1281-1288.
9. Cruchaga C., et al. “Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer’s disease”. Human Molecular Genetics 21 (2012): 4558-4571.
10. Wahrle SE., et al. “Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms”. Molecular Neurodegeneration 2 (2077): 7-13.
11. Olsson B., et al. “Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer’s disease and vascular dementia”. Journal of Alzheimer's Disease 34 (2013): 673-679.
12. Doody RS., et al. “Phase 3 trials of solanezumab for mildto-moderate Alzheimer’s disease”. The New England Journal of Medicine 370 (2014): 311-321.
13. Liu Y., et al. “Biomarkers in Alzheimer’s disease analysis by mass spectrometry-based proteomics”. International Journal of Molecular Sciences 15 (2014): 7865-7882.
14. Spencer JP. “Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain”. Proceedings of the Nutrition Society 2 (2010): 244-260.
15. Andersen JK. “Oxidative stress in neurodegeneration: Cause or consequence?” Nature Medicine 10 (2004): S18-25.
16. Ganesan A. “The impact of natural products upon modern drug discovery”. Current Opinion in Chemical Biology 3 (2008): 306-317.
17. Koehn FE. “High impact technologies for natural products screening”. Progress in Drug Research 175 (2008): 177-210.
18. Spires-Jones TL and Hyman BT. “The intersection of amyloid beta and tau at synapses in Alzheimer’s disease”. Neuron 82 (2014): 756-771.
19. Haass C., et al. “Trafficking and proteolytic processing of APP”. Cold Spring Harbor Perspectives in Medicine 2 (2012): a006270.
20. Tanzi RE. “The genetics of Alzheimer disease”. Cold Spring Harbor Perspectives in Medicine 2 (2012): 1-10.
21. Merxmuller H., et al. In: J.B. Heywood J.B, Harborne B and Turner L. The Biology and Chemistry of Compositae. Academic Press, New York (1977): 590.
22. Tackholm V. “Students Flora of Egypt”. Cairo University, Beirut (1974): 562.
23. Tackholm V. “Alfred Kaiser’s Sinai-Herbarium”. Cairo University Herbium, Cairo (1969): 562.
24. Ahmed AA and Jakupovic. “Sesqui and monoterpenes from Jasonia montana”. Phytochemistry 29 (1990): 3656-3661.
25. Eid F., et al. “Constituents from Jasonia montana and Allagopuppus dicotoma”. Pharmazie 42 (1987): 423-24.
26. Ahmed AA., et al. “11-Hydrojasionone A new sesquiterpene type from Jasonia montana”. Phytochemistry 27 (1988): 3875-3877.
27. Ahmed AA. “Two geraniol derivatives from Jasonia montana”. Pharmazie 46 (1991): 362-63
28. Ahmed AA., et al. “Flavonoid aglycones from Jasonia montana”. Phytochemistry 28 (1989): 665-667.
29. El-gizawy HA and Hussein MA. “Fatty acids Profile, Nutritional Values, Anti-diabetic and Antioxidant Activity of the Fixed Oil of Malva parviflora Growing in Egypt”. International Journal of Phytomedicine 7 (2015): 219-230.
30. Hussein MA. “Antidiabetic and antioxidant activity of Jasonia montana extract in streptozotocin-induced diabetic rats”. Saudi Pharmaceutical Journal 16 (2008): 3-4.
31. Hussein MA and Farghaly HS. “Protective Effects of Jasonia montana Against Lipid Peroxidation in Liver and Kidney of Iron-overloaded Rats”. Australian Journal of Basic and Applied Sciences7 (2010): 2004-2012.
32. Hussein MA and Abdelgawad S. “Protective effect of Jasonia montana against ethinylestradiol-induced cholestasis in rats”. Saudi Pharmaceutical Journal 18 (2010): 27-33.
33. Hussein MA. “Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation in obese diabetic rats fed high-fat diet”. Free Radicals and Antioxidants 1 (2011): 51-62.
34. Hammerschmidt FJ., et al. “Chemical composition, and antimicrobial activity of essential oils of Jasonia candicans and Jasonia montana”. Planta Medica 59 (1993): 68-70.
35. Milad R and Maliheh S. “Comparison of Memory Impairment and Oxidative Stress Following Single or Repeated Doses Administration of Scopolamine in Rat Hippocampus”. BCN 1 (2018): 5-14.
36. Laxmi AP., et al. “Evaluation of neuroprotective effect of quercetin with donepezil in scopolamine-induced amnesia in rats”. Indian Journal of Pharmacology 1 (2017): 60-64.
37. Fossati P and Prencipe L. “Plasma triacylglycerols determined calorimetrically with an enzyme that produces hydrogen peroxide”. Clinical Chemistry 1 (1982): 2077-2080.
38. Allain CC., et al. “Enzymatic determination of total serum cholesterol”. Clinical Chemistry 4 (1974): 470-475.
39. Friedewald WT. “Estimation of concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge”. Clinical Chemistry 18 (1972): 499-502.
40. Tokeo S and Sakanashi M. “Characterization of membrane bound adenosine triphosphatase activity of enriched fraction from vascular smooth muscle”. Enzyme 34 (1985): 152-165.
41. Bancroft GD and Steven A. “Theory and Practice of Histological Technique”. 4th ed. Churchill Livingstone, New York (1983): 99-112.
42. Han XQ., et al. “Long-term fatty liver-induced insulin resistance in orotic acid-induced nonalcoholic fatty liver rats”. Bioscience, Biotechnology, and Biochemistry 4 (2016): 735-743.
43. Liu XF., et al. “Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice”. Lipids in Health and Disease 12 (2013): Artn 109.
44. Scicchitano P., et al. “Nutraceuticals and dyslipidaemia: Beyond the common therapeutics”. Journal of Functional Foods 6 (2014): 11-32.
45. Quinn JF., et al. “Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial”. JAMA17 (2010): 1903-1911.
46. Saw CLL., et al. “Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid”. Biochemical Pharmacology 3 (2010): 421-430.
47. Abdalla FH., et al. “Neuroprotective effect of quercetin in ectoenzymes and acetylcholinesterase activities in cerebral cortex synaptosomes of cadmium-exposed rats”. Molecular and Cellular Biochemistry 381 (2013): 1-8.
48. Safarinejad MR., et al. “Relationship of omega-3 and omega-6 fatty acids with semen characteristics, and anti-oxidant status of seminal plasma: a comparison between fertile and infertile men”. Clinical Nutrition1 (2010): 100-105.
49. Sherif F., et al. “Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer’s disease”. Journal of Neural Transmission: Parkinson's Disease a and Dementia Section 3 (1992): 227-240.
50. Gaweska H., et al. “Structures and mechanism of the monoamine oxidase family”. Biomolecular Concepts5 (2011): 365-377.
51. Delgado PL., et al. “Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression”. Psychopharmacology Bulletin 3 (1991): 45-52.
52. Cai Z. “Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer’s disease (Review)”. Molecular Medicine Reports 5 (2014): 1533-1541.
53. Hroudová J., et al. “Progress in drug development for Alzheimer’s disease: An overview in relation to mitochondrial energy metabolism”. European Journal of Medicinal Chemistry 46 (2016): 165-174.
54. Saada HN., et al. “Fish oil omega-3 fatty acids reduce the severity of radiation-induced oxidative stress in the rat brain”. International Journal of Radiation Biology 12 (2014): 1179-1183.
55. Christian B., et al. “Chronic aspartame affects T‐maze performance, brain cholinergic receptors and Na+, K+‐ATPase in rats”. Pharmacology Biochemistry and Behavior 78 (2004): 121-127.
56. Morris RG., et al. “Elements of a neurobiological theory of the hippocampus: the role of activity‐dependent synaptic plasticity in memory”. Philosophical Transactions of the Royal Society B 358 (2003): 773-786.
57. Sato T., et al. “Effects of steroid hormones on (Na+, K+) ‐ATPase activity inhibition‐induced amnesia on the step‐through passive avoidance task in gonadectomized mice”. Pharmacology Research 49 (2004): 151-159.
58. Scuri R., et al. “Inhibition of Na+/K+ ATPase potentiates synaptic transmission in tactile sensory neurons of the leech”. European Journal of Neuroscience 25 (2007): 159-167.
59. Saini N., et al. “Neuroprotective effects of Bacopa monnieri in experimental model of dementia”. Neurochemistry Research 37 (2012): 1928-1937.
60. Zhang L., et al. “Na (+)/K (+) ‐ATPase inhibition upregulates NMDA‐evoked currents in rat hippocampal CA1 pyramidal neurons”. Fundamental and Clinical Pharmacology 26 (2012): 503-512.
61. Wang Y-M., et al. “Effects of different dietary phospholipids on lipid metabolism and brain phospholipids fatty acid composition in rats”. China Oils and Fats2 (2012): 31-34.
62. Rogers SL., et al. “Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group”. Archives of Internal Medicine9 (1998): 1021-1031.
63. Goh CW., et al. “Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats”. Drug Metabolism and Disposition: the Biological Fate of Chemicals3 (2011): 402-411.
64. Boudrault C., et al. “Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer’s disease”. Journal of Nutritional Biochemistry 1 (2009): 1-10.
65. Tackholm V. “Alfred Kaiser’s Sinai-Herbarium, 1969 p. 562. Cairo University Herbium, Cairo. 21. Ahmed AA, Jakupovic. Sesqui and monoterpenes from Jasonia montana”. Journal of Phytochemistry 29 (1990): 3656-3661.
66. Eid F., et al. “Constituents from Jasonia montana and Allagopuppus dicotoma”. Pharmazie 42 (1987): 423-24.
67. Ahmed AA., et al. “Flavonoid aglycones from Jasonia montana”. Phytochemistry 28 (1989): 665-667.
68. Ahmed AA. “Two geraniol derivatives from Jasonia montana”. Pharmazie 46 (1991): 362-363.
69. Bouktaib, M. “Regio-and stereoselective synthesis of the major metabolite of quercetin, quercetin-3-O-b-D-glucuronide”. Tetrahedron Letters 43 (2002): 6263-6266.
70. Graf B. “Flavonols, flavones, flavanones, and human health: epidemiological evidence”. Journal of Medicinal Food 8 (2008): 281-290.
71. Grune T and Berger MM. “Markers of oxidative stress in ICU clinical settings: present and future”. Current Opinion in Clinical Nutrition and Metabolic Care 17 (2007): 545-551.
72. Ishisaka A., et al. “Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats”. Free Radical Biology and Medicine 51 (2011): 1329-1336.
73. Dajas F. “Life or death: neuroprotective and anticancer effects of quercetin”. Journal of Ethnopharmacology 143 (2012): 383-396.

Citation

Citation: Mohammed A Hussein., et al. “Jasonia Montana; A Promising Therapeutic Agent to Attenuate Neurological Disorders Associated with SCO-induced Dementia".Acta Scientific Nutritional Health 5.7 (2021): 27-37.

Copyright

Copyright: © 2021 Mohammed A Hussein., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.